A Phase 2/3 interventional study of Amoxicillin in Community-acquired Pneumonia, sponsored by St. Justine's Hospital. Recruiting at 1 site in Canada. Open to participants aged 3 Months to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by St. Justine's Hospital · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing amoxicillin in Community-Acquired Pneumonia — 5 open to participants now, 5 under way, 2 of them phase 3. Amoxicillin · Community-Acquired Pneumonia.
Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, this one has the largest planned enrollment, is the only one that started in 2017, is the only one in phase 2/3, and was the 5th registered.
325 studies on the registry are indexed under Community-Acquired Pneumonia; 77 are open to participants now.
Browse Community-Acquired Pneumonia studies →5 of the 12 studies testing amoxicillin in Community-Acquired Pneumonia are open now, in 4 countries. Recruiting first, the newest first:
Medical College of Wisconsin · Sites in United States
Ages 3 mo–18 yrs
Nantes University Hospital · Sites in France
Ages 65+
Khyber Teaching Hospital · Sites in Pakistan
Ages 3 mo–5 yrs
RESnTEC, Institute of Research · Sites in Pakistan
Ages 2–5
By country, each count listing its studies:
Amoxicillin: first FDA approval 1974 (AMOXIL). What it is approved for, and how studies give it, is on its page →
Of the 41 Community-Acquired Pneumonia studies recruiting now, 29 (71%) set no upper age limit and 9 (22%) stop at 75 or younger; 13 take children under 18; 5 take healthy volunteers.
This study: 3 Months to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 1 · Phase 3 2 · Phase 4 5
First in 2005; this study’s year is marked. 1 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,370 is above the median of 246 across 196 interventional studies indexed under Community-Acquired Pneumonia.
Median enrollment 243 across the 12 interventional studies. Of the 7 that completed or were terminated, 1 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 12 has an industry lead sponsor. The 10 most frequent:
St. Justine's Hospital is the lead sponsor of 156 studies on the registry; 27 are open to participants now.
St. Justine's Hospital has 1 study filed under Community-Acquired Pneumonia — fewer than ten, so there is no comparison to draw.
3 of the studies testing amoxicillin in Community-Acquired Pneumonia that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06229288Phase 3Nantes University HospitalAmoxicillin Alone Versus Amoxicillin/Clavulanate for Community-acquired Pneumonia in Patients Aged 65 Years or Older, and Hospitalized in a Non-intensive Care Unit Ward | 2027-05-25 |
| NCT03031210Phase 3St. Justine's HospitalTwice Daily Treatment With Amoxicillin for Non-severe Community Acquired Pneumonia. | 2027-06-01 |
| NCT07647835Khyber Teaching Hospital3 vs. 5 Days of Amoxicillin for Childhood Pneumonia: An RCT | 2027-06-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 12 studies testing amoxicillin in Community-Acquired Pneumonia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study will be to evaluate whether a twice-daily antibiotic regimen is non-inferior to a thrice-daily regimen for the treatment of non-severe community acquired pneumonia in children presenting at a paediatric Emergency Department (ED).
A single-center, non-blinded, pragmatic, randomized-controlled, non-inferiority clinical trial will be conducted in an urban, university-affiliated, tertiary care pediatric hospital ED. All patients three months old to 18 years of age who had symptoms and signs suggestive of non-severe community acquired pneumonia based on respiratory complaints and a pulmonary infiltrate identified by trained paediatricians or emergency physicians will be eligible to the present study. Study participants will be randomly allocated to receive either amoxicillin (90mg/kg per day) in twice or thrice daily regimen. Primary outcome will be treatment failure within 10 days of enrolment as defined by hospitalisation, need for a change in antibiotic (persistence of fever at 72 hours, clinical deterioration, comorbid condition or development of serious adverse reactions) and death. ED revisits within 72 hours, second course of antibiotic and clinical recurrence rates will be evaluated in the follow-up assessments as well as percent of adverse events encountered, number of days missed (work, school or daycare), coverage vaccination rate, protocol adherence and patient and parental satisfaction. The primary analysis will use an intention-to-treat approach. Per-protocol analysis will also be carried to compare the failure rate. Accounting to a maximal 10% drop-off rate, a sample size of 685 participants per arm was calculated to have a power of 90% to identify a difference of ≤ 5% with an alpha value of 0.05.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All patients 3 months to 18 years of age attending the pediatric ED and diagnosed with a non-severe pneumonia, will be considered for enrolment. More precisely, the following inclusion criteria will be required:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients will received a prescription of amoxicillin (90mg/kg/day) divided in two doses daily.
Drug: Amoxicillin
Patients will received a prescription of amoxicillin (90mg/kg/day) divided in three doses daily.
Drug: Amoxicillin
(90 mg/kg/day) twice daily
Also known as: Amoxil
Clinical failure within 10 days of enrolment
As a primary outcome, clinical failure will be defined by any of the following occurring within 10 days of enrolment: * Death or hospitalisation * A need for a change in antibiotic according to the treating physician. In our settings, common reasons to change antibiotic are: * Persistence of fever at 72h * Clinical deterioration: • Clinical deterioration will include the development of lower chest-wall indrawing, central cyanosis, stridor while calm, or danger signs as defined by: inability to drink or breastfeed, convulsions, persistent vomiting, lethargy, or unconsciousness at any time during a child's treatment. * Development of a comorbid condition such as a meningitis, bacteriemia, osteomyelitis or septic arthritis * Allergic reaction
Time frame: Day 10 (after enrolment)
Emergency department revisit within 72 hours
Return to the emergency department in the following 72 hours
Time frame: 72 hours
Second course of antibiotic
Necessity of second course of antibiotics
Time frame: 1 month
Clinical recurrence
Another diagnosis of pneumonia
Time frame: 1 month
Adverse events
Any adverse event
Time frame: 10 days
Number of working days missed by caregivers or school/daycare days missed by patients
Total number of days missed by caregivers or school/daycare days missed by the parents
Time frame: 1 month
Patient's and parents satisfaction with the discharge instructions' provided and the ease of administration
Measured on a likert scale through a telephone survey
Time frame: 10 days
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2017 (actual). Primary completion is estimated for Jun 2027, 119 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amoxicillin
Community-Acquired Pneumonia →